© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 23, 2032-2038,
December 1, 1999
© 1999 Oxford University Press
REPORTS |
Implications and Prognostic Value of K-ras Mutation for Early-Stage Lung Cancer in Women
Affiliations of authors: H. H. Nelson, K. T. Kelsey, Department of Cancer Cell Biology, Harvard School of Public Health, Boston, MA; D. C. Christiani, Occupational Health Program, Harvard School of Public Health, and Pulmonary and Critical Care Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston; E. J. Mark (Department of Pathology), J. C. Wain (Thoracic Surgery Unit, Department of Surgery), Massachusetts General Hospital, Harvard Medical School; J. K. Wiencke, Laboratory for Molecular Epidemiology, Department of Epidemiology and Biostatistics, University of California at San Francisco.
Correspondence to: Karl T. Kelsey, M.D., M.O.H., Department of Cancer Cell Biology, Harvard School of Public Health, 665 Huntington Ave., Bldg. 1, Rm. 207, Boston, MA 02115-6021.
BACKGROUND: Because there is no clear consensus as to the predictive value of K-ras gene mutation for survival in patients with lung cancer, we examined the occurrence of K-ras mutations in a large, prospective case series of non-small-cell lung cancer (NSCLC). Our goals were to define the patient characteristics associated with K-ras mutation and to determine whether mutation of this gene might be a biomarker of patient prognosis. METHODS: Consecutive, newly diagnosed patients with lung cancer treated with potentially curative resection over a 4-year period were recruited for study. The mutation status of K-ras codon 12 in each patient's tumor DNA was determined by means of polymerase chain reaction-restriction fragment length polymorphism analysis of archived pathology specimens. Analyses were restricted to adenocarcinoma. RESULTS: There was a statistically significant association between female sex and K-ras mutation after adjustment for carcinogen exposures (odds ratio = 3.3; 95% confidence interval [CI] = 1.3-7.9); mutations were found only in smokers. Comparison of Kaplan-Meier curves indicated a strong association between K-ras mutation and decreased patient survival (two-sided P = .009); analysis stratified by pathologic staging groups revealed that this association was statistically significant only for stage I tumors (two-sided P = .002). Cox proportional hazards modeling indicated that K-ras codon 12 mutation was a statistically significant predictor of patient survival, after adjustment for the effects of age, sex, and stage (risk ratio = 1.8; 95% CI = 1.1-3.1). CONCLUSIONS: After adjustment for environmental exposures, non-small-cell lung tumors in women appear to be more likely than those in men to harbor K-ras mutations, suggesting a possible role of estrogen exposure in either the initiation or the selection of K-ras mutant clones in adenocarcinoma. In addition, our data suggest that K-ras codon 12 mutation is a marker of aggressive NSCLC, as evidenced by its association with decreased patient survival, particularly for early-stage disease.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. R. Blumenschein Jr, U. Gatzemeier, F. Fossella, D. J. Stewart, L. Cupit, F. Cihon, J. O'Leary, and M. Reck Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., September 10, 2009; 27(26): 4274 - 4280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Sartori, A. Cavazza, A. Sgambato, A. Marchioni, F. Barbieri, L. Longo, M. Bavieri, B. Murer, E. Meschiari, S. Tamberi, et al. EGFR and K-ras Mutations Along the Spectrum of Pulmonary Epithelial Tumors of the Lung and Elaboration of a Combined Clinicopathologic and Molecular Scoring System to Predict Clinical Responsiveness to EGFR Inhibitors Am J Clin Pathol, April 1, 2009; 131(4): 478 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Riely, M. G. Kris, D. Rosenbaum, J. Marks, A. Li, D. A. Chitale, K. Nafa, E. R. Riedel, M. Hsu, W. Pao, et al. Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma Clin. Cancer Res., September 15, 2008; 14(18): 5731 - 5734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Hammoud, B. Tan, S. Badve, and R. M Bigsby Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma Endocr. Relat. Cancer, June 1, 2008; 15(2): 475 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Wisnivesky and E. A. Halm Sex Differences in Lung Cancer Survival: Do Tumors Behave Differently in Elderly Women? J. Clin. Oncol., May 1, 2007; 25(13): 1705 - 1712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Toschi and F. Cappuzzo Understanding the New Genetics of Responsiveness to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Oncologist, February 1, 2007; 12(2): 211 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Marsit, E. A. Houseman, B. C. Christensen, K. Eddy, R. Bueno, D. J. Sugarbaker, H. H. Nelson, M. R. Karagas, and K. T. Kelsey Examination of a CpG Island Methylator Phenotype and Implications of Methylation Profiles in Solid Tumors Cancer Res., November 1, 2006; 66(21): 10621 - 10629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Ganti, A. E. Sahmoun, A. W. Panwalkar, K. K. Tendulkar, and A. Potti Hormone Replacement Therapy Is Associated With Decreased Survival in Women With Lung Cancer J. Clin. Oncol., January 1, 2006; 24(1): 59 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Hutt, B. R. Vuillemenot, E. B. Barr, M. J. Grimes, F. F. Hahn, C. H. Hobbs, T. H. March, A. P. Gigliotti, S. K. Seilkop, G. L. Finch, et al. Life-span inhalation exposure to mainstream cigarette smoke induces lung cancer in B6C3F1 mice through genetic and epigenetic pathways Carcinogenesis, November 1, 2005; 26(11): 1999 - 2009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. H. Nelson, M. Wilkojmen, C. J. Marsit, and K. T. Kelsey TP53 mutation, allelism and survival in non-small cell lung cancer Carcinogenesis, October 1, 2005; 26(10): 1770 - 1773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Thomas, L. A. Doyle, and M. J. Edelman Lung Cancer in Women: Emerging Differences in Epidemiology, Biology, and Therapy Chest, July 1, 2005; 128(1): 370 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Patel Lung Cancer in Women J. Clin. Oncol., May 10, 2005; 23(14): 3212 - 3218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Janne, J. A. Engelman, and B. E. Johnson Epidermal Growth Factor Receptor Mutations in Non-Small-Cell Lung Cancer: Implications for Treatment and Tumor Biology J. Clin. Oncol., May 10, 2005; 23(14): 3227 - 3234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Sridhar, D. Hedley, and L. L. Siu Raf kinase as a target for anticancer therapeutics Mol. Cancer Ther., April 1, 2005; 4(4): 677 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.C. AMLER, A.D. GODDARD, and K.J. HILLAN Predicting Clinical Benefit in Non-Small-Cell Lung Cancer Patients Treated with Epidermal Growth Factor Tyrosine Kinase Inhibitors Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 483 - 488. [Abstract] [PDF]
|
|
|
|
|
|
C. J. Marsit, M. Hasegawa, T. Hirao, D.-H. Kim, K. Aldape, P. W. Hinds, J. K. Wiencke, H. H. Nelson, and K. T. Kelsey Loss of Heterozygosity of Chromosome 3p21 Is Associated with Mutant TP53 and Better Patient Survival in Non-Small-Cell Lung Cancer Cancer Res., December 1, 2004; 64(23): 8702 - 8707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Olak and Y. Colson Gender differences in lung cancer: Have we really come a long way, baby? J. Thorac. Cardiovasc. Surg., September 1, 2004; 128(3): 346 - 351. [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Patel, P. B. Bach, and M. G. Kris Lung Cancer in US Women: A Contemporary Epidemic JAMA, April 14, 2004; 291(14): 1763 - 1768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Moore, C. M. Mery, M. T. Jaklitsch, A. P. Estocin, R. Bueno, S. J. Swanson, D. J. Sugarbaker, and J. M. Lukanich Menopausal effects on presentation, treatment, and survival of women with non-small cell lung cancer Ann. Thorac. Surg., December 1, 2003; 76(6): 1789 - 1795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Garcia-Rostan, H. Zhao, R. L. Camp, M. Pollan, A. Herrero, J. Pardo, R. Wu, M. L. Carcangiu, J. Costa, and G. Tallini ras Mutations Are Associated With Aggressive Tumor Phenotypes and Poor Prognosis in Thyroid Cancer J. Clin. Oncol., September 1, 2003; 21(17): 3226 - 3235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Ahrendt, Y. Hu, M. Buta, M. P. McDermott, N. Benoit, S. C. Yang, L. Wu, and D. Sidransky p53 Mutations and Survival in Stage I Non-Small-Cell Lung Cancer: Results of a Prospective Study J Natl Cancer Inst, July 2, 2003; 95(13): 961 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Brundage, D. Davies, and W. J. Mackillop Prognostic Factors in Non-small Cell Lung Cancer* : A Decade of Progress Chest, September 1, 2002; 122(3): 1037 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. P. Stabile, A. L. G. Davis, C. T. Gubish, T. M. Hopkins, J. D. Luketich, N. Christie, S. Finkelstein, and J. M. Siegfried Human Non-Small Cell Lung Tumors and Cells Derived from Normal Lung Express Both Estrogen Receptor {alpha} and {beta} and Show Biological Responses to Estrogen Cancer Res., April 1, 2002; 62(7): 2141 - 2150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Ahrendt, S. C. Yang, L. Wu, C. M. Roig, P. Russell, W. H. Westra, J. Jen, M. V. Brock, R. F. Heitmiller, and D. Sidransky Molecular assessment of lymph nodes in patients with resected stage I non-small cell lung cancer: Preliminary results of a prospective study J. Thorac. Cardiovasc. Surg., March 1, 2002; 123(3): 466 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Wolf, Y. C. Hu, K. Doffek, D. Sidransky, and S. A. Ahrendt O6-Methylguanine-DNA Methyltransferase Promoter Hypermethylation Shifts the p53 Mutational Spectrum in Non-Small Cell Lung Cancer Cancer Res., November 1, 2001; 61(22): 8113 - 8117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Adjei Blocking Oncogenic Ras Signaling for Cancer Therapy J Natl Cancer Inst, July 18, 2001; 93(14): 1062 - 1074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sanchez-Cespedes, P. A. Decker, K. M. Doffek, M. Esteller, W. H. Westra, E. A. Alawi, J. G. Herman, M. J. Demeure, D. Sidransky, and S. A. Ahrendt Increased Loss of Chromosome 9p21 but not p16 Inactivation in Primary Non-Small Cell Lung Cancer from Smokers Cancer Res., March 1, 2001; 61(5): 2092 - 2096. [Abstract] [Full Text]
|
|
|
|
|
|
M. Sanchez-Cespedes, S. A. Ahrendt, S. Piantadosi, R. Rosell, M. Monzo, L. Wu, W. H. Westra, S. C. Yang, J. Jen, and D. Sidransky Chromosomal Alterations in Lung Adenocarcinoma from Smokers and Nonsmokers Cancer Res., February 1, 2001; 61(4): 1309 - 1313. [Abstract] [Full Text]
|
|
|
|
|
|
J. H. Schiller, S. Adak, R. H. Feins, S. M. Keller, W. A. Fry, R. B. Livingston, M. E. M. Hammond, B. Wolf, L. Sabatini, J. Jett, et al. Lack of Prognostic Significance of p53 and K-ras Mutations in Primary Resected Non-Small-Cell Lung Cancer on E4592: A Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy J. Clin. Oncol., January 15, 2001; 19(2): 448 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hirao, H. H. Nelson, T. D. S. Ashok, J. C. Wain, E. J. Mark, D. C. Christiani, J. K. Wiencke, and K. T. Kelsey Tobacco Smoke-induced DNA Damage and an Early Age of Smoking Initiation Induce Chromosome Loss at 3p21 in Lung Cancer Cancer Res., January 1, 2001; 61(2): 612 - 615. [Abstract] [Full Text]
|
|
|
|
|
|
M.J. Lafuente, X. Casterad, M. Trias, C. Ascaso, R. Molina, A. Ballesta, S. Zheng, J.K. Wiencke, and A. Lafuente NAD(P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors Carcinogenesis, October 1, 2000; 21(10): 1813 - 1819. [Abstract] [Full Text] [PDF]
|
|